January 1978

Diabetes and Glomerulopathies-Reply

Arch Intern Med. 1978;138(1):164. doi:10.1001/archinte.1978.03630250109035

This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.


In Reply.—  The three cases reported on by Dr Lindeman are very interesting, albeit enigmatic because of incomplete information. We, of course, are cognizant of the description of glomerular hypercellularity and of crescents in diabetes. In addition to the histological, immunological, and immunofluorescence findings observed in our patients, however, they also displayed characteristic clinical courses not likely to be attributable to diabetes alone. Thus, the development of a reversible vascular congestive state in two patients, and acute irreversible renal failure in the third is most compatible with the proposed, superimposed renal diseases rather than with diabetes. We have no evidence of an increased incidence of glomerulonephritis among diabetics.INDEX TO ADVERTISERS A Abbott Laboratories.......... 19, 156-158 Ayerst Laboratories........ 101, 142-144 B Boehringer Ingelheim, Ltd........... 2nd Cover-2, 49-52 Burroughs Wellcome Company.. 20-22 D Dista Products Company........ 131-132 Dow Pharmaceuticals.......... 112-114 E Endo Laboratories.......... 102-104 H Hoechst-Roussel Pharmaceuticals, Inc........... 74-76 L Lilly,

First Page Preview View Large
First page PDF preview
First page PDF preview